{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362262946285996288.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1053/j.gastro.2003.09.026"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S001650850301518X?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S001650850301518X?httpAccept=text/plain"}},{"identifier":{"@type":"NAID","@value":"30023017952"}}],"dc:title":[{"@value":"Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382262946285996290","@type":"Researcher","foaf:name":[{"@value":"George K.K Lau"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262946285996291","@type":"Researcher","foaf:name":[{"@value":"Harry H.Y Yiu"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262946285996297","@type":"Researcher","foaf:name":[{"@value":"Daniel Y.T Fong"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262946285996295","@type":"Researcher","foaf:name":[{"@value":"Hoi-Ching Cheng"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262946285996292","@type":"Researcher","foaf:name":[{"@value":"Wing-Yan Au"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262946285996296","@type":"Researcher","foaf:name":[{"@value":"Lydia S.F Lai"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262946285996289","@type":"Researcher","foaf:name":[{"@value":"Micheal Cheung"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262946285996288","@type":"Researcher","foaf:name":[{"@value":"Hai-Ying Zhang"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262946285996298","@type":"Researcher","foaf:name":[{"@value":"Albert Lie"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262946285996294","@type":"Researcher","foaf:name":[{"@value":"Roger Ngan"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262946285996293","@type":"Researcher","foaf:name":[{"@value":"Raymond Liang"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00165085"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/00165085"}],"prism:publicationName":[{"@value":"Gastroenterology"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2003-12","prism:volume":"125","prism:number":"6","prism:startingPage":"1742","prism:endingPage":"1749"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S001650850301518X?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S001650850301518X?httpAccept=text/plain"}],"createdAt":"2005-07-29","modifiedAt":"2019-03-09","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360283693322566144","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Novel monitoring of hepatitis B reactivation based on ultra‐high sensitive hepatitis B surface antigen assay"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285711733152384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294740589267968","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298757420671744","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360306905605133824","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical usefulness of an ultra-high-sensitivity hepatitis B surface antigen assay to determine the cessation of treatment for HBV reactivation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185479120640","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical evaluation of a novel and highly sensitive immunoassay for anti‐hepatitis B core antigen using a fully automated immunochemical analyzer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360568466082640384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846642463453952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204790262400","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A non-Hodgkin lymphoma patient with reactivation of HBV during chemotherapy and emergence of a YMDD-motif mutant on lamivudine, eventually controlled by adfovil dipovoxil"},{"@language":"ja","@value":"ＮＨＬに対する化学療法中にＹＭＤＤ変異によりＨＢＶ再活性化をきたし，ａｄｅｆｏｖｉｒ　ｄｉｐｉｖｏｘｉｌ追加投与にて改善した１例"},{"@value":"症例報告 NHLに対する化学療法中にYMDD変異によりHBV再活性化をきたし,adefovir dipivoxil追加投与にて改善した1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク NHL ニ タイスル カガク リョウホウチュウ ニ YMDD ヘンイ ニ ヨリ HBV サイカッセイカ オ キタシ adefovir dipivoxil ツイカ トウヨ ニテ カイゼンシタ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390845713049085952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1570291225220602240","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Fatal Fulminant Hepatitis B after Withdrawal of Prophylactic Lamivudine in Hematopoietic Stem Cell Transplantation Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1570291226066662016","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"B型肝炎再活性化による劇症肝炎の現状と対策"},{"@language":"en","@value":"Current status and prevention of fulminant hepatitis due to hepatitis B reactivation"}]},{"@id":"https://cir.nii.ac.jp/crid/1574231875740606208","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"モニタリングによるB型肝炎再活性化の予防"},{"@language":"en","@value":"Preemptive therapy for HBV reactivation by serial HBV-DNA monitoring"}]},{"@id":"https://cir.nii.ac.jp/crid/2050870367073795072","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1053/j.gastro.2003.09.026"},{"@type":"CIA","@value":"30023017952"},{"@type":"CROSSREF","@value":"10.1007/s10157-011-0464-7_references_DOI_QVm81H8NX83Bhq6qU9DcJJJHK0i"},{"@type":"CROSSREF","@value":"10.1111/liv.13349_references_DOI_QVm81H8NX83Bhq6qU9DcJJJHK0i"},{"@type":"CROSSREF","@value":"10.1182/asheducation-2014.1.576_references_DOI_QVm81H8NX83Bhq6qU9DcJJJHK0i"},{"@type":"CROSSREF","@value":"10.2957/kanzo.48.309_references_DOI_QVm81H8NX83Bhq6qU9DcJJJHK0i"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.1587-18_references_DOI_QVm81H8NX83Bhq6qU9DcJJJHK0i"},{"@type":"CROSSREF","@value":"10.1007/s00535-022-01872-w_references_DOI_QVm81H8NX83Bhq6qU9DcJJJHK0i"},{"@type":"CROSSREF","@value":"10.1111/hepr.13864_references_DOI_QVm81H8NX83Bhq6qU9DcJJJHK0i"},{"@type":"CROSSREF","@value":"10.1016/j.aohep.2024.101764_references_DOI_QVm81H8NX83Bhq6qU9DcJJJHK0i"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_QVm81H8NX83Bhq6qU9DcJJJHK0i"},{"@type":"CROSSREF","@value":"10.1111/hepr.13229_references_DOI_QVm81H8NX83Bhq6qU9DcJJJHK0i"},{"@type":"CROSSREF","@value":"10.1007/s12072-019-09988-7_references_DOI_QVm81H8NX83Bhq6qU9DcJJJHK0i"},{"@type":"CROSSREF","@value":"10.1093/cid/civ344_references_DOI_QVm81H8NX83Bhq6qU9DcJJJHK0i"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_QVm81H8NX83Bhq6qU9DcJJJHK0i"}]}